Issue link: https://beckershealthcare.uberflip.com/i/1255100
35 Executive Briefing Everything in Moderation – Excessive UV-C energy, i.e. close application for long periods of time, can cause surface damage, especially to some plastics. There is a tradeoff between cycle length, efficacy and the risk of surface damage. Know how to manage the tradeoffs. Considerations / questions for hospital executives when choosing UV-C technology: 1. Efficacy a. Do cycle times enable effective patient flow? b. Does the device kill pathogens of concern in realistic contact times? c. Does the device effectively direct energy to both horizontal and vertical surfaces? 2. Safety a. Does the device have multiple safety features to ensure staff, patients and visitors are shielded from UV-C energy? 3. Portability a. Is the device easy to transport within and between facilities, or does it require special handling? b. Is the device compact enough to both use and store in tight spaces? c. Does the unit weight allow all staff to handle the unit easily? 4. Durability a. Will the device stand up to repeated use associated with terminal / discharge cleaning and transport? b. Are the device and bulbs protected during transport and storage? 5. Usability a. Is the devise easy to set up, reposition and operate? b. Are the cycle times required short enough to incorporate into the discharge workflow process? c. Can the device be stored at the point of use to reduce transport time? 6. Affordability a. What is the acquisition cost of the device? b. What are the operating costs (parts, labor, etc.)? c. What is the total cost to run – including the device, labor and time that the room is out of service? d. What are the options for acquisition (purchase, lease, rent)? e. What are the expected service / maintenance costs once purchased? f. Is a warranty / service contract provided? How long? How much? 7. Manufacturer support a. Does the manufacturer provide tools to demonstrate the effectiveness of the device? b. What training and tools are provided to ensure smooth operationalization? c. What reporting tools are provided? d. What is the ongoing support for service and any repair? Incorporating any new technologies into a workflow can create new challenges. Diversey can help by providing a full implementation and training plan to help your team successfully operationalize the program and optimize the return on investment, helping you realize the benefits of the UV-C technology as part of your arsenal to reduce HAIs. Conclusion In the battle to create a safer and more satisfying environment for patients, UV-C technology can provide an added layer of assurance to manual cleaning and disinfection programs, lowering risk for staff and patients, and ultimately reducing the risk and financial burden of HAIs. For more information on Diversey's MoonBeam™3 UVC disinfection device, go to https://bit.ly/3bCR6Bf. n References 1. CDC, 2015, https://www.cdc.gov/hai/data/portal/index.html 2. Carling ICHE 11/2008, Improving Cleaning of the Environment Surrounding Patients in 36 Acute Care Hospitals 3. Jefferson, 2011, A Novel Technique for Identifying Opps to Improve Environmental Hygiene in the OR 4. Otter, 2013, Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings 5. Anderson Lancet, 2017 Anderson DJ, Chen LF, Weber DJ, Moehring RW, et al. Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study. Lancet 2017;389(10071):805-14 6. Anderson DJ, Moehring RW, Weber DJ, Lewis SS, Chen LF, Schwab JC, Becherer P, Blocker M, Triplett PF, Knelson LP, Lokhnygina Y, Rutala WA, Sexton DJ, for the CDC Prevention Epicenters Program. Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection). Lancet 2018; published online June 4, 2018. 7. Kaufmann, 2010, NCBI, The human intra-S checkpoint response to UVC-induced DNA damage. 8. Cadnum 2016, Infection Control & Hospital Epidemiology / Volume 37 / Issue 05 / May 2016, pp 555 - 560, Effect of Variation in Test Methods on Performance of Ultraviolet-C Radiation Room Decontamination 9. Boyce, 2019, Infection Control & Hospital Epidemiology (2019), 40, 1030 –1035, Understanding ultraviolet light surface decontamination in hospital rooms: A primer Diversey is a market leader who provides a total solution for infection prevention, including resources to address emerging needs, facilitation of evidence-based cleaning and disinfection practices, and products which enhance patient safety and drive improved productivity while lowering the overall cost. We feel that each of these components is paramount to driving improved patient outcomes.